Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

12
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
12
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

3.9K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.9K
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

51
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
51
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

13
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
13
Acute Kidney Injury III: Clinical Manifestations01:29

Acute Kidney Injury III: Clinical Manifestations

52
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
52
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

212
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
212

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Increased awareness around an ultra-rare disease can improve diagnosis delays: the French example in primary hyperoxalurias.

Orphanet journal of rare diseases·2026
Same author

The European Society of Pediatric Nephrology Board Examination-a certified benchmark of knowledge and clinical practice with global recognition.

Pediatric nephrology (Berlin, Germany)·2026
Same author

Outcomes and Validation of Histopathological Scores in Pediatric ANCA-vasculitis.

Kidney international reports·2026
Same author

Optimizing risk-benefit in highly sensitized kidney recipient antigen delisting increasing donor access.

Kidney international·2026
Same author

Toward personalized medicine in childhood nephrotic syndrome.

Kidney international·2026
Same author

Epidemiology and prognosis of childhood lupus nephritis in the Afro-descendant population of the French Overseas Departments of America.

BMC nephrology·2026
Same journal

Barriers, Breakthroughs, and the Future of Pediatric Dermatologic Care.

Pediatric clinics of North America·2026
Same journal

Advancing Pediatric Dermatology: Innovations in Care and Access.

Pediatric clinics of North America·2026
Same journal

No Child Left Behind: Advancing Access in Pediatric Dermatology, a 4-Year, Single-Center Experience.

Pediatric clinics of North America·2026
Same journal

Telemedicine and Access to Pediatric Dermatology Care.

Pediatric clinics of North America·2026
Same journal

Inequitable Reimbursement for Pediatric Providers: A Review of Structural Factors that Disincentivize the Care of Children.

Pediatric clinics of North America·2026
Same journal

Medical Photography's Power to Change Medical Care.

Pediatric clinics of North America·2026
See all related articles

Related Experiment Video

Updated: Aug 7, 2025

Separation of Immune Cell Subpopulations in Peripheral Blood Samples from Children with Infectious Mononucleosis
08:44

Separation of Immune Cell Subpopulations in Peripheral Blood Samples from Children with Infectious Mononucleosis

Published on: September 7, 2022

2.5K

Hemolytic-Uremic Syndrome in Children.

Olivia Boyer1, Patrick Niaudet2

  • 1Pediatric Nephrology, Necker Enfants Malades Hospital, Université Paris Cité, France; Néphrologie Pédiatrique, Hôpital Necker, 149 Rue de Sèvres, Paris 75015, France.

Pediatric Clinics of North America
|March 7, 2023
PubMed
Summary
This summary is machine-generated.

Hemolytic uremic syndrome (HUS) is a severe condition often caused by E. coli. While typical HUS management is supportive, atypical HUS benefits from complement inhibitors like eculizumab.

Keywords:
Alternative pathway of complementEculizumabHemolytic uremic syndromeShiga toxinThrombotic microangiopathy

More Related Videos

Assessment of Intestinal Transcytosis of Neonatal Escherichia coli Bacteremia Isolates
08:32

Assessment of Intestinal Transcytosis of Neonatal Escherichia coli Bacteremia Isolates

Published on: February 17, 2023

1.4K
Rapid Depletion of Renal Macrophages using Human CD59/Intermedilysin Cell Ablation Tool
09:58

Rapid Depletion of Renal Macrophages using Human CD59/Intermedilysin Cell Ablation Tool

Published on: May 9, 2025

291

Related Experiment Videos

Last Updated: Aug 7, 2025

Separation of Immune Cell Subpopulations in Peripheral Blood Samples from Children with Infectious Mononucleosis
08:44

Separation of Immune Cell Subpopulations in Peripheral Blood Samples from Children with Infectious Mononucleosis

Published on: September 7, 2022

2.5K
Assessment of Intestinal Transcytosis of Neonatal Escherichia coli Bacteremia Isolates
08:32

Assessment of Intestinal Transcytosis of Neonatal Escherichia coli Bacteremia Isolates

Published on: February 17, 2023

1.4K
Rapid Depletion of Renal Macrophages using Human CD59/Intermedilysin Cell Ablation Tool
09:58

Rapid Depletion of Renal Macrophages using Human CD59/Intermedilysin Cell Ablation Tool

Published on: May 9, 2025

291

Area of Science:

  • Nephrology
  • Hematology
  • Infectious Diseases

Background:

  • Hemolytic uremic syndrome (HUS) presents with a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney failure.
  • Shiga-toxin-producing bacteria, particularly Escherichia coli (STEC), are the primary cause of typical HUS.
  • STEC-HUS is a leading cause of acute renal failure in pediatric populations.

Purpose of the Study:

  • To summarize the characteristics and management of typical and atypical HUS.
  • To highlight the role of Shiga-toxin-producing bacteria in HUS etiology.
  • To discuss the therapeutic advancements in atypical HUS.

Main Methods:

  • Literature review of HUS cases and management strategies.
  • Analysis of etiological factors, including bacterial toxins and genetic variants.
  • Evaluation of treatment outcomes for supportive care and targeted therapies.

Main Results:

  • Typical HUS, often linked to STEC from contaminated food, requires supportive care with variable outcomes.
  • Atypical HUS (aHUS), accounting for 5% of cases, involves complement pathway dysregulation and has a high risk of end-stage renal disease.
  • Genetic variants in complement regulators are implicated in aHUS, leading to a relapsing course.

Conclusions:

  • Management of typical HUS remains primarily supportive.
  • Atypical HUS necessitates specific treatments targeting the complement system.
  • Complement inhibitors, exemplified by eculizumab, have significantly improved the prognosis for atypical HUS patients.